TP53 Mutation Immunotherapy: One Gene, Opposite Outcomes
TP53 mutations reshape the tumor immune microenvironment and set the terms for checkpoint blockade. TP53 mutation immunotherapy response is therefore context dependent: in lung adenocarcinoma the mutation marks a hotter tumor and predicts longer progression-free survival on anti-PD-1 therapy, while in TP53-mutant myeloid leukemia a cold, suppressed niche blunts that benefit. One gene, opposite outcomes.
Why TP53 status rewires the tumor immune microenvironment
TP53 sits on chromosome 17p13.1 and is the most frequently altered gene across human cancers, mutated in more than 50 percent of malignancies and in over 70 percent of esophageal squamous cell carcinoma, small cell lung cancer, squamous lung cancer, and complex-karyotype acute myeloid leukemia. For decades p53 was cast as a controller of cell-cycle arrest, apoptosis, and DNA repair. Work now shows the mutant protein actively shapes the tumor immune microenvironment, turning TP53 from an undruggable tumor suppressor into a biomarker and combination target for TP53 mutation immunotherapy and immune checkpoint inhibitor therapy.
The p53 protein is a 393-amino-acid transcription factor with five domains: the N-terminal transactivation domain (residues 1 to 61), the proline-rich domain (62 to 94), the central DNA-binding domain (95 to 292), the tetramerization domain (325 to 356), and the C-terminal regulatory domain (357 to 393). The DNA-binding domain is the most mutation-prone region. Loss of zinc stabilization at the L2 and L3 loops destroys DNA-binding specificity. The dominant hotspot residues are R248, R249, G245, R282, and R175. Myeloid tumors share R175, R248, R273, and R282 but add the distinctive hotspots Y220 and M237.
A single missense change can exert a dominant-negative effect: mutant p53 forms tetramers with wild-type protein and silences the remaining wild-type allele. Beyond loss of function, many missense mutants gain oncogenic function through new interactions with other transcription factors, driving metabolic reprogramming, blocking apoptosis, and suppressing cytotoxic autophagy. p53 can also be inactivated by deletion, alternative splicing, post-translational modification, or MDM2 and MDM4 upregulation.
| p53 domain | Residues | Core function |
| Transactivation domain (TAD) | 1 to 61 | Recruits transcription machinery |
| Proline-rich domain (PRD) | 62 to 94 | Apoptosis and stability control |
| DNA-binding domain (DBD) | 95 to 292 | Mutates most often; sets specificity |
| Tetramerization domain (TD) | 325 to 356 | Enables tetramer assembly |
| C-terminal regulatory domain (CTD) | 357 to 393 | Fine-tunes DNA binding |
How wild-type p53 builds an immunopermissive niche
Wild-type p53 constructs a pro-inflammatory, antigen-presenting microenvironment through several coordinated routes. It degrades the DNA exonuclease TREX1, lets cytoplasmic DNA accumulate, and switches on the cGAS-STING cytosolic DNA sensing pathway. The cascade moves cytoplasmic DNA to cGAS dimerization and cGAMP production, STING trafficking to the Golgi where it meets TBK1 and IRF3, IRF3 phosphorylation and dimerization into the nucleus, and type I interferon induction. Wild-type p53 also drives IFN-alpha, IFN-beta, and CCL2 secretion and tunes Toll-like receptor activity.
It strengthens antigen presentation. MDM2 inhibitor treatment in mouse syngeneic models raises antigen-presenting CD103-positive CD11c-positive dendritic cells and triggers immune surveillance. p53 influences MHC class I surface expression, induces TAP1, and through BATF3 upregulates Ly6C-positive CD103-positive antigen-presenting cells. It lowers PD-L1 and activates natural killer cells: wild-type p53 raises miR-34a and ULBP1 and ULBP2. miR-34a suppresses PD-L1 mRNA translation and speeds its decay, freeing CD8-positive T cells to kill; ULBP1 and ULBP2 are natural killer activating ligands. p53 also restrains PD-1 and PD-L1 checkpoint molecules to hold immune balance. Finally it pushes M1 polarization by suppressing MYC, cutting the immunosuppressive M2 polarization of macrophages and lifting anti-tumor cytokines.
How mutant p53 builds an immunosuppressive niche
Mutant p53 systematically dismantles that balance. It binds TBK1 and blocks downstream cGAS-STING signaling, preventing IRF3 phosphorylation and enabling immune escape; over-expressing TBK1 competitively frees TBK1 from mutant p53, re-activates IRF3, and slows tumor growth. Gain-of-function p53 suppresses DAB2IP and promotes TNF-induced NF-kappaB activation, while p53 loss drives glycolytic overactivation that feeds NF-kappaB, closing a pro-inflammatory and pro-survival loop.
Myeloid reprogramming follows. p53 loss raises CXCR3 secretion and recruits immunosuppressive CD11b-positive myeloid cells; it lifts CXCL17 and CXCL15 to attract CD45-positive GR-1-positive CD11b-positive myeloid-derived suppressor cells. Distinct missense mutants shed miR-1246-rich exosomes that reprogram nearby macrophages into M2-like tumor-associated macrophages secreting IL-10, TNF, CCL2, and TGF-beta. T cells are suppressed and Tregs polarized: p53 loss promotes CXCR3 and CCR2 chemokines and CSF-1, indirectly weakening CD8-positive and CD4-positive type 1 helper responses, while p53 mutation induces Treg differentiation through FOXP3 and reduces CD8-positive cytotoxic lymphocytes by inducing tumor granzyme B. Natural killer cells desensitize: mutants G242A and G245A impair MULT-1 and HA60a, and miR-519a-3p lowers NKG2D ligands ULBP2 and MICA. Neutrophils and stroma remodel through WNT or IL-1beta, JAK2-STAT3, and CXCL1 or CXCL5; the R172H gain-of-function mutant drives intra-tumoral neutrophils via CXCL2 with fewer CD4-positive and CD8-positive T cells. Mutant p53 also loads normal fibroblasts with mutant protein through extracellular vesicles, pushing cancer-associated fibroblast traits, and via EMMPRIN, TIMP3, MMP9, and MMP2 reshapes the extracellular matrix while HIF-1 induces VEGF and PDGF to flip the angiogenesis switch.
| TP53 allelic state in myeloid tumors | Share of TP53-mutant cases | Note |
| Two or more mutations | 18.4 to 28.8 percent | Biallelic inactivation |
| Single mutation plus trans wild-type deletion | 22.5 to 42.2 percent | Biallelic inactivation |
| Single mutation plus copy-neutral LOH | 12.2 to 20.6 percent | Biallelic inactivation |
| Overall biallelic inactivation | about 76 percent | Worse leukemia risk |
| Multi-hit median overall survival | 8.7 months | vs 2.5 years single-allele |
TP53 mutation immunotherapy: one mutation, opposite outcomes
Tumor type decides whether TP53 mutation immunotherapy helps or hurts. The evidence splits cleanly by malignancy, so the mutation must be read inside its tumor context rather than as a standalone flag.
Non-small cell lung cancer: the strongest positive signal
A multi-omics study of 23 treatment-naive non-small cell lung cancer samples integrated whole-exome sequencing, single-cell RNA sequencing, and spatial transcriptomics, validated in cohorts of 510 and 110 tumors plus a multiplex immunofluorescence set. TP53-mutant lung adenocarcinoma showed more exhausted-like T cells and GZMK-positive CD8-positive T cells but fewer tissue-resident memory CD4-positive T cells, a signature that is more immunogenic yet more suppressed. Multiple checkpoint pathways co-activated: PD-1 to PD-L1 and TIGIT to PVR between T cells and cancer cells, and CTLA4 to CD86 and HAVCR2 to LGALS9 across T cells and myeloid cells. TIGIT is the most widely expressed checkpoint on T and natural killer cells, and its ligand PVR runs higher on TP53-mutant malignant cells. Spatial transcriptomics confirmed tighter TIGIT and PVR co-localization. In a large clinical cohort, TP53-mutant lung adenocarcinoma carrying dominant-negative, loss-of-function, or high-impact class II mutations lived longer without progression on anti-PD-1 therapy.
Comutation data sharpen the picture. Expert consensus notes that among KRAS-mutant non-small cell lung cancer, concurrent TP53 mutation adds benefit while STK11 or KEAP1 co-mutation predicts poor outcome. Even with STK11 or KEAP1 co-mutation, retrospective analyses of three large trials showed immunotherapy beating chemotherapy alone, with overall survival hazard ratios of 0.75 and 0.81. In a study of 696 patients with PD-L1 above 50 percent, KRAS mutation appeared in 53 percent and TP53 mutation in 51 percent. Median treatment time was 8.6 months overall but 13.7 months for KRAS G12C with TP53 mutation. Response rates were 69.7 percent versus 46.5 percent for wild-type, and 55.4 percent versus 39.5 percent otherwise; dual-mutant patients on PD-1 inhibition alone surpassed five years overall survival.
TP53-mutant MDS and AML: a cold, resistant niche
About 10 percent of myelodysplastic syndrome and acute myeloid leukemia carry TP53 mutation, rising to 70 percent in complex-karyotype myeloid tumors. The niche is cold: hematopoietic stem cells overexpress PD-L1 with lowered PD-1, bone marrow loses cytotoxic and helper T cells and natural killer cells, and Tregs and myeloid-derived suppressor cells dominate. The myeloid checkpoint LILRB3 rises on TP53-mutant cells and tracks with leukemia cell survival and lost T-cell cytotoxicity. A 61-patient trial of azacitidine with or without durvalumab showed T-cell exhaustion phenotypes in TP53-mutant acute myeloid leukemia, and one cycle nearly reversed PD-1, PD-L1, and PD-L2 methylation, though whether that raises checkpoint expression and resistance is unsettled.
Clinical results stay flat. Nivolumab (Opdivo) with azacitidine in 70 relapsed or refractory acute myeloid leukemia cases, 16 with TP53 mutation, gave a median overall survival of only 6 months in the TP53 group. Nivolumab with cytarabine and idarubicin in newly diagnosed disease with 8 TP53-mutant patients reached 18.54 months. Among untreated myelodysplastic syndrome, azacitidine plus nivolumab gave the best response at 55 percent. By contrast, sabatolimab, an anti-TIM-3 agent, with azacitidine or decitabine reached 71.4 percent response and 21.5 months median duration in high-risk myelodysplastic syndrome with TP53 mutation. A warning from the CAR-T era: treatment-related myeloid neoplasms after CAR-T carry a three-year cumulative incidence of 7.5 to 9 percent, and TP53 mutation sits in 44.4 to 50 percent of those cases, mostly arising within a year and often present before CAR-T.
Biliary tract cancer: an open question
A 2025 analysis of advanced biliary tract cancer pooled Japanese and United States databases of first-line checkpoint-treated patients. TP53 mutation appeared in 52.4 percent of 594 Japanese cases. KRAS, ERBB2, CDKN2A, and SMAD4 changes clustered in the mutant group; IDH1, BAP1, and FGFR2 fusions in the wild-type group. Multivariate analysis tagged TP53 mutation as an independent adverse factor for progression-free survival. The same dataset has not yet reported the full immune-versus-non-immune comparison or the T-cell dysfunction and exclusion signature details, so no firm claim on checkpoint benefit in biliary tract cancer is possible yet.
Diffuse large B-cell lymphoma: p53 loss drives T-cell exhaustion
In diffuse large B-cell lymphoma classification, the A53 subtype defined by TP53 mutation and deletion covers 20 to 30 percent of cases and marks high risk. TP53 mutation breaks G1 to S and G2 to M checkpoints, lowers DNA repair, and raises genomic instability, feeding immune escape, clonal diversity, and T-cell exhaustion. p53 loss also raises PD-L1 and drops MHC class II, worsening exhaustion and pairing with constitutive NF-kappaB activation in the ABC subtype. Clinically, TP53-mutant diffuse large B-cell lymphoma responds poorly to R-CHOP and loses about 40 percent of median overall survival versus wild-type disease.
| Tumor type | TP53 mutation as ICI marker | Key data |
| Lung adenocarcinoma | Favorable | Longer PFS on anti-PD-1; ORR 69.7 vs 46.5 percent with KRAS G12C |
| KRAS G12C plus TP53 | Favorable | Median treatment 13.7 months; OS past 5 years |
| MDS or AML | Poor or limited | Cold niche; median OS 6 months with nivolumab plus azacitidine |
| Biliary tract cancer | Unresolved | 52.4 percent mutant; adverse for PFS, ICI data pending |
| Diffuse large B-cell lymphoma | Poor | A53 subtype 20 to 30 percent; about 40 percent shorter OS |
The paradox: worse prognosis, better checkpoint response
The puzzle is that TP53 mutation predicts poor prognosis in non-small cell lung cancer, biliary tract cancer, diffuse large B-cell lymphoma, and myeloid leukemia, yet in lung adenocarcinoma it predicts longer progression-free survival on anti-PD-1 therapy. The mutation appears to lift both the tumor aggressiveness curve and the immune visibility curve at once; the net effect depends on whether checkpoint blockade releases the brake. This is the core reason TP53 mutation immunotherapy must be read tumor by tumor.
Combination strategies that target p53 and immunity
Several p53-directed agents pair with checkpoint blockade. APR-246, also called eprenetapopt, restores wild-type activity to mutant p53 and stabilizes wild-type protein. With azacitidine in two phase 2 studies it gave 52 percent and 71 percent response, 37 percent and 44 percent complete response, and 12.1 and 10.8 months median overall survival, but a phase 3 trial missed its primary endpoint at 35 percent versus 22 percent twelve-month complete response. The MDM2 inhibitor alrizomadlin (APG-115) with pembrolizumab (Keytruda) was tested in immune-resistant solid tumors; the pair beat either alone in models, and the effect vanished in Trp53-knockout mice, proving p53 activation is required to remodel the niche. Rezatapopt, a reactivator of the Y220C mutant, reached 20 percent overall response across advanced solid tumors in a published phase 1 study.
Gene therapy adds options. CXCR4-targeted mRNA nanoparticles induce wild-type p53 and, paired with anti-PD-1, reprogram the niche and improve outcomes. These agents are the practical frontier of TP53 mutation immunotherapy, pairing direct p53 biology with checkpoint release. Adoptive cell therapy and bispecific antibodies exploit p53 neoantigens: T-cell receptor engineered T cells recognize common mutant p53 epitopes, splice-site mutants being especially immunogenic; a bispecific single-chain antibody against the R175H neoepitope kills R175H tumors despite very low peptide density. Therapeutic vaccines use long synthetic peptides, viral vectors, or dendritic cells pulsed with wild-type and modified p53 peptides, with early signal in advanced breast cancer. STING agonists aim to revive innate and adaptive immunity in the suppressed myeloid niche, though one early trial stopped early for financial reasons.
| Agent or approach | Target | Setting | Reported result |
| Eprenetapopt (APR-246) | Mutant p53 reactivation | MDS or AML with azacitidine | 52 to 71 percent response; phase 3 missed endpoint |
| Alrizomadlin (APG-115) | MDM2 inhibitor | Solid tumors with pembrolizumab | Synergy lost in p53-null models |
| Rezatapopt | Y220C reactivation | Advanced solid tumors | 20 percent overall response (phase 1) |
| p53 mRNA nanoparticles | Wild-type p53 expression | With anti-PD-1 | Niche reprogramming |
| Sabatolimab | Anti-TIM-3 | High-risk MDS with TP53 | 71.4 percent response; 21.5 months duration |
| p53 neoantigen vaccines | Mutant or shared p53 | Early clinical | Immune signal in breast cancer |
Practical takeaways for clinicians and trial designers
- Read TP53 status inside the tumor type, never in isolation. It is a positive marker in lung adenocarcinoma and a weak or negative one in TP53-mutant myeloid leukemia.
- Place TP53 with its co-mutation context. KRAS with TP53 helps; STK11 or KEAP1 with TP53 predicts resistance in non-small cell lung cancer.
- Move past mutant versus wild-type. Trial designs should record mutation type, allelic state, variant allele frequency, and co-mutations.
- For cold myeloid niches, prefer myeloid-checkpoint or STING combinations over single-agent checkpoint blockade.
- Track emerging p53 reactivators, mRNA nanoparticles, and neoantigen vaccines as the field matures, because TP53 mutation immunotherapy will advance through these combinations rather than single agents.
Limitations
This review draws on published mechanism studies, conference abstracts, and trial reports available through mid-2026, with no external supplementation. Some datasets are incomplete: the biliary tract cancer comparison of immune versus non-immune outcomes, the T-cell dysfunction signature details, and the serum p53 antibody association with response were not fully reported and are described qualitatively. A few mechanisms, such as the miR-34a to PD-L1 axis, rest on diagrammatic source interpretations and warrant confirmation against primary literature. Effect sizes vary by assay and cohort, and single-arm trial data cannot establish causality.
Bottom line
TP53 mutation immunotherapy is not one story but many. Wild-type p53 licenses an immunopermissive niche; mutant p53 builds suppression while keeping high immunogenicity and multi-checkpoint co-activation. Clinically the mutation is a favorable checkpoint marker in lung adenocarcinoma, a poor one in TP53-mutant myeloid leukemia, and unresolved in biliary tract cancer and diffuse large B-cell lymphoma. Precise functional stratification, not a simple mutant-or-wild-type call, will convert this biomarker into a target.
FAQ
Does TP53 mutation predict response to immunotherapy?
Yes, but the direction depends on tumor type. In lung adenocarcinoma, TP53 mutation tracks higher PD-L1 and richer interferon-gamma signaling, which predicts longer progression-free survival on anti-PD-1 therapy. In TP53-mutant myelodysplastic syndrome and acute myeloid leukemia, a cold niche with few effector cells limits that benefit. The mutation is therefore a context-dependent marker, not a universal switch for response.
Why does TP53 mutation help in lung cancer but not in leukemia?
The tumor immune microenvironment decides the outcome. Lung adenocarcinoma with TP53 mutation stays hot: it raises PD-L1, TIGIT to PVR signaling, and T-cell infiltration that checkpoint blockade can engage. TP53-mutant myeloid leukemia is cold, with lost T cells, natural killer cells, and a dominant Treg and myeloid-derived suppressor niche, leaving little for immunotherapy to release.
What is the cGAS-STING pathway role in p53 immunity?
Wild-type p53 degrades the exonuclease TREX1, lets cytoplasmic DNA build up, and switches on cGAS-STING, which induces type I interferons and antigen presentation. Mutant p53 binds TBK1 and blocks this axis, preventing IRF3 activation and enabling immune escape. Over-expressing TBK1 can free the complex and restore interferon signaling, which is why this node is a target for combination immunotherapy.
How KRAS STK11 and KEAP1 co-mutations change the picture?
Among KRAS-mutant non-small cell lung cancer, adding TP53 mutation improves checkpoint response, while adding STK11 or KEAP1 predicts poor outcome. Even with those adverse co-mutations, immunotherapy still beat chemotherapy alone in large trials, with overall survival hazard ratios near 0.75 to 0.81. TP53 must therefore be read inside the full co-mutation frame, never as a lone flag.
What is gain-of-function in mutant p53?
Gain-of-function means a missense mutant p53 gains pro-tumor activities. It forms new interactions with other transcription factors, drives metabolic reprogramming, blocks apoptosis, and suppresses autophagy. These mutants also build an immunosuppressive niche through exosomes, myeloid and Treg recruitment, and natural killer desensitization, which is why they matter for TP53 mutation immunotherapy response.
Which drugs target mutant p53 directly?
Eprenetapopt restores wild-type activity to mutant p53 and, with azacitidine, reached 52 to 71 percent response in myeloid trials. Rezatapopt reactivates the Y220C mutant and gave 20 percent response across solid tumors in phase 1. The MDM2 inhibitor alrizomadlin pairs with pembrolizumab, and p53 mRNA nanoparticles, neoantigen vaccines, and STING agonists form the broader combination pipeline now in early testing.
Is TP53 mutation a good or bad prognosis sign?
Both. TP53 mutation predicts worse overall survival across lung, biliary, lymphoma, and myeloid cancers, yet in lung adenocarcinoma it predicts longer progression-free survival on anti-PD-1 therapy. The mutation appears to raise tumor aggressiveness and immune visibility together; checkpoint blockade captures the visibility half. Prognosis and checkpoint benefit therefore point in opposite directions for the same alteration.
What is the A53 subtype in diffuse large B-cell lymphoma?
The A53 subtype is defined by TP53 mutation and deletion and covers 20 to 30 percent of diffuse large B-cell lymphoma cases, marking high risk. It breaks cell-cycle checkpoints, lowers DNA repair, and raises genomic instability, which drives immune escape and T-cell exhaustion. p53 loss also raises PD-L1 and drops MHC class II, and these tumors respond poorly to R-CHOP with about 40 percent shorter survival.
How common is TP53 mutation across cancers?
TP53 is mutated in more than 50 percent of human malignancies overall and in over 70 percent of esophageal squamous cell carcinoma, small cell lung cancer, squamous lung cancer, and complex-karyotype acute myeloid leukemia. In myelodysplastic syndrome and acute myeloid leukemia about 10 percent carry the mutation, rising to 70 percent in complex-karyotype disease, where biallelic inactivation reaches about 76 percent.
What combinations work best in TP53-mutant myeloid leukemia?
Single-agent checkpoint blockade fares poorly there, with median overall survival near 6 months. The stronger signal comes from myeloid-checkpoint agents: sabatolimab, an anti-TIM-3 antibody with azacitidine or decitabine, reached 71.4 percent response and 21.5 months median duration. STING agonists aim to revive innate immunity in the cold niche, though one early trial stopped early for financial reasons with outcome pending.
Can p53 neoantigens be used as vaccines?
Yes. Most p53 mutations stabilize the protein and raise intratumoral p53, and shared wild-type fragments appear widely, so therapeutic vaccines can induce tumor-specific T cells without autoimmunity. Long synthetic peptides, viral vectors, and dendritic cells pulsed with p53 peptides have shown immune signal, including in advanced breast cancer. Splice-site mutants are especially immunogenic, fueling adoptive cell therapy.
What should future TP53 immunotherapy trials measure?
Trials should move past mutant versus wild-type and record mutation type, allelic state, variant allele frequency, and co-mutations, since these shift the effect. For TP53-mutant myeloid leukemia, molecularly defined cohorts and biomarkers beyond cytogenetics and variant allele frequency are needed. New p53 reactivators, mRNA nanoparticles, and bispecific antibodies deserve dedicated, stratified evaluation.
